A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )

Launched by PRIME MEDICINE, INC. · Aug 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new type of gene therapy called Prime Editing (PM359) for people with a genetic condition known as autosomal recessive Chronic Granulomatous Disease (CGD). This condition is caused by a mutation in a specific gene (NCF1) that makes it difficult for the body to fight off infections. The trial aims to find out if using edited stem cells from the patient's own body can help improve their health and reduce the risks of severe infections related to CGD.

To be eligible for this study, participants must be diagnosed with CGD due to the delGT mutation in the NCF1 gene and have received treatment for at least the past two years. They should also have experienced at least one severe infection related to CGD or have an ongoing infection that is hard to treat. If you join this study, you’ll receive personalized treatment and be monitored closely for safety and effectiveness over a total of 15 years. This trial is currently recruiting participants of all ages, and it is important to note that certain health conditions may prevent someone from being eligible.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Autosomal recessive Chronic Granulomatous Disease due to the delGT mutation in NCF1 causing dysfunction of p47phox
• • Treated and followed for at least the past 2 years in a specialized center
• • Willingness to participate in this study as well as a long-term follow-up study with the understanding that the total participation is 15 years
• • At least 1 prior severe CGD-related infection OR an ongoing severe CGD-related infection requiring therapy or that is refractory to standard therapy; OR an autoimmune or inflammatory condition related to CGD that is active or requiring therapy to maintain remission.
• Exclusion Criteria:
• • For participants younger than 16 years of age: known, willing, and available 10/10 (A,B,C,DR,DQ) HLA-matched related donor (10/10 MRD)
• • Active bacteremia or fungemia
• • Ongoing inflammatory condition that is ≥ CTCAE v5.0 Grade 3 despite high-dose steroids (≥ 0.5 mg/kg/day of prednisone and/or equivalent).
• * Any contraindication which in the opinion of the transplant physician would make the participant ineligible to undergo autologous HSCT, including, but not limited to:
• • 1. Contraindication to mobilization and apheresis, including severe allergic reaction to receipt of any medication or other drug substance required for mobilization and apheresis (e.g., G-CSF, plerixafor) or PM359 manufacture (e.g., DMSO).
• • 2. Contraindication to receipt of the conditioning agent, busulfan.
• • Positive for presence of human immunodeficiency virus (HIV)-1 or HIV-2, or active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV).
• • Inadequate organ function, including known chronic advanced end-organ damage which in the opinion of the investigator would put the participant at risk for undergoing HSCT
• • Prior or current malignancy or myeloproliferative disorder (excluding Stage 1 or lower, fully treated/excised malignant and pre-malignant disease of the skin, cervix or colon).
• • Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the participant or would preclude the participant from successful study completion, including Participant/Parent/Guardian unable or unwilling to comply with the protocol requirements.
• • Pregnancy or breastfeeding in a postpartum female or absence of adequate contraception for fertile participants. Females of childbearing potential and non-sterile male participants who are or may become sexually active with female partners of childbearing potential are required to use highly effective contraception from Screening through at least 12 months after drug product infusion.
• • Participation in another clinical study with an investigational drug within 30 days of Screening or at least 5 times the half-life of the investigational drug (whichever is longer), or any prior receipt of gene therapy or hematopoietic stem cell transplant.